Mereo BioPharma Group Yönetim

Yönetim kriter kontrolleri 3/4

Mereo BioPharma Group CEO'su Denise Scots-Knight, Jul2015 tarihinde atandı, in görev süresi 9.33 yıldır. in toplam yıllık tazminatı $ 2.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.5% maaş ve 74.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.9% ine doğrudan sahiptir ve bu hisseler € 10.40M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.7 yıl ve 3.6 yıldır.

Anahtar bilgiler

Denise Scots-Knight

İcra Kurulu Başkanı

US$2.2m

Toplam tazminat

CEO maaş yüzdesi	25.5%
CEO görev süresi	9.3yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	6.7yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Denise Scots-Knight'un ücretlendirmesi Mereo BioPharma Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	US$2m	US$565k	-US$29m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$2m	US$507k	-US$42m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$2m	US$539k	US$17m
Sep 30 2021	n/a	n/a	-US$10m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$131m
Dec 31 2020	US$1m	US$545k	-US$224m
Sep 30 2020	n/a	n/a	-US$198m
Jun 30 2020	n/a	n/a	-US$177m
Mar 31 2020	n/a	n/a	-US$111m
Dec 31 2019	US$2m	US$518k	-US$46m
Sep 30 2019	n/a	n/a	-US$41m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$41m
Dec 31 2018	US$957k	US$484k	-US$41m
Sep 30 2018	n/a	n/a	-US$42m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$50m
Dec 31 2017	US$907k	US$493k	-US$52m

Tazminat ve Piyasa: Denise 'nin toplam tazminatı ($USD 2.22M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.03M ).

Tazminat ve Kazançlar: Denise 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Denise Scots-Knight (65 yo)

9.3yrs

Görev süresi

US$2,219,323

Tazminat

Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Denise Scots-Knight	Co-Founder	9.3yrs	US$2.22m	1.9% € 10.4m
Charles Sermon	Co-Founder	9.5yrs	US$1.09m	0.58% € 3.2m
Christine Fox	Chief Financial Officer	3.8yrs	US$1.00m	0.27% € 1.5m
John Richard	Co-Founder & Chief Business Officer	9.8yrs	Veri yok	Veri yok
John Lewicki	Chief Scientific Officer	4.3yrs	Veri yok	0.060% € 328.1k
Jackie Parkin	Senior VP & Therapeutic Head	no data	Veri yok	Veri yok
Alexandra Hughes-Wilson	Chief of Patient Access & Commercial Planning	6.7yrs	Veri yok	0.033% € 178.4k
Suba Krishnan	Senior Vice President of Clinical Development	3.9yrs	Veri yok	Veri yok
Bo Kara	Senior VP and Head of Pharmaceutical Development & CMC	no data	Veri yok	Veri yok

6.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: MAH0 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Denise Scots-Knight	Co-Founder	9.7yrs	US$2.22m	1.9% € 10.4m
Michael Wyzga	Independent Non-Executive Chairman of The Board	5.6yrs	US$156.80k	0.016% € 88.5k
Deepika Pakianathan	Independent Non-Executive Director	5.6yrs	US$113.76k	0% € 0
Anders Ekblom	Independent Non-Executive Director	9.3yrs	US$121.31k	0.17% € 904.5k
Marc Yoskowitz	Independent Director	2yrs	US$94.49k	0.049% € 266.5k
Annalisa Lisa Jenkins	Independent Director	2yrs	US$100.96k	0.049% € 266.5k
Jeremy Bender	Independent Non Executive Director	4.1yrs	US$105.08k	0.0081% € 44.3k
Daniel Shames	Independent Director	2yrs	US$97.75k	0.049% € 266.5k
Pierre Jacquet	Independent Director	3.2yrs	US$102.18k	0.10% € 546.5k
Justin Roberts	Independent Director	2yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MAH0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Mereo BioPharma Group Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Mereo Biopharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Board Changes

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Less than half of directors are independent

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Astrazeneca Reportedly Considering Take over Offer for Mereo

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Mereo BioPharma Group plc has completed a Follow-on Equity Offering in the amount of $100.05 million.

Mereo BioPharma Group plc, Annual General Meeting, Feb 01, 2021

Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma Provides Update with Respect to the Cancellation of Admission of Its Ordinary Shares to Trading on Aim

Mereo Biopharma Group plc Announces the Appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, Effective December 7, 2020

Mereo BioPharma Group Plans Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

Mereo BioPharma Group plc Announces Changes to Board of Directors

Mereo Biopharma Group plc Receives U.S. Food and Drug Administration Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

Mereo BioPharma Group plc Announces Initiation of Placebo-Controlled Phase 1B/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş